BiotechTube

Tenapanor

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

IBS

Conditions

IBS, IBS - Irritable Bowel Syndrome

Trial Timeline

Feb 6, 2024 → Dec 17, 2025

NCT ID
NCT05995899

About Tenapanor

Tenapanor is a approved stage product being developed by Ardelyx for IBS. The current trial status is completed. This product is registered under clinical trial identifier NCT05995899. Target conditions include IBS, IBS - Irritable Bowel Syndrome.

What happened to similar drugs?

1 of 5 similar drugs in IBS were approved

Approved (1) Terminated (0) Active (4)
🔄linaclotide + PlaceboAstellas PharmaPhase 3
🔄Placebo + LinaclotideAstraZenecaPhase 3
✅TegaserodNovartisApproved
🔄TenapanorArdelyxPhase 3
🔄Tenapanor 50 MG + Tenapanor 25 mg bid + PlaceboArdelyxPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT06810167Phase 3Recruiting
NCT05995899ApprovedCompleted
NCT06203444Phase 1Completed
NCT05905926Phase 3Recruiting
NCT04549597ApprovedCompleted
NCT02727751Phase 3Completed

Competing Products

12 competing products in IBS

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
linaclotide + PlaceboAstellas PharmaPhase 3
40
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisApproved
43
SMS995 + PlaceboNovartisPhase 1
29
DNK333 + PlaceboNovartisPhase 2
35
TenapanorArdelyxPhase 3
41
Tenapanor 50 MG + Tenapanor 25 mg bid + PlaceboArdelyxPhase 3
41
Tenapanor + PlaceboArdelyxPhase 2
36
MD-7246 + PlaceboIronwood PharmaceuticalsPhase 2
29